A
LRMR icon

AlphaQuest’s Larimar Therapeutics LRMR Stock Holding History

AlphaQuest’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,183
Closed -$60.1K – 1884
2024
Q3 		$60.1K Buy
9,183
+5,796
+171% +$46.6K 0.01% 1378
2024
Q2 		$24.6K Sell
3,387
-6,886
-67% -$52.7K ﹤0.01% 1280
2024
Q1 		$78K Buy
+10,273
New +$80K 0.01% 867

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

AlphaQuest's LRMR Position: Q4 2024 in Review

AlphaQuest sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 9,183 shares — an estimated $60.1K sold.

AlphaQuest first reported a position in LRMR in Q1 2024 and held it in 3 quarters. The position peaked at $78K in Q1 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

  • AlphaQuest reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaQuest sold 9,183 Larimar Therapeutics shares in Q4 2024, an estimated $60.1K.
  • AlphaQuest first reported a position in Larimar Therapeutics in Q1 2024 and held it in 3 quarters.
  • AlphaQuest's Larimar Therapeutics position peaked at $78K in Q1 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on AlphaQuest's 13F filing for Q4 2024, filed 7 Feb 2025.